Cerebrospinal Fluid Matrix Metalloproteinases Are Elevated in Cerebral Adrenoleukodystrophy and Correlate with MRI Severity and Neurologic Dysfunction

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Thibert, Kathryn A ^a   Raymond, Gerald V ^b   Nascene, David R ^a   Miller, Weston P ^a   Tolar, Jakub ^a   Orchard, Paul J ^a   Lund, Troy C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADRENOLEUKODYSTROPHY; APHASIA; APRAXIA; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN FUNCTION; CEREBRAL ADRENOLEUKODYSTROPHY; CEREBRAL BLINDNESS; CLINICAL ARTICLE; CLINICAL FEATURE; COMMUNICATION DISORDER; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DYSPHAGIA; ENCEPHALITIS; HEARING IMPAIRMENT; HUMAN; HYPERREFLEXIA; INCONTINENCE; INFANT; LOES SCORING SYSTEM; MALE; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCORING SYSTEM; SEIZURE; SPASTICITY; UPREGULATION; VISUAL IMPAIRMENT;

ADRENOLEUKODYSTROPHY; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUTATION; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84869852211     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050430     Document Type: Article

References (30)

1. Ferrer I, Aubourg P, Pujol A, (2010) General aspects and neuropathology of X-linked adrenoleukodystrophy. Brain Pathol 20: 817-830.
2. Peters C, (2004) Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 104: 881-888.
3. Paintlia AS, Gilg AG, Khan M, Singh AK, Barbosa E, et al. (2003) Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies. Neurobiol Dis 14: 425-439.
4. Deon M, Wajner M, Sirtori L, Fitarelli D, Coelho D, et al. (2006) The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy. Journal of the Neurological Sciences 247: 157-164.
5. Lepperta D, Lindbergb RLP, Kapposa L, Leibc SL, (2001) Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Research Reviews 36: 249-257.
6. Bora A, Anderson C, Bachani M, Nath A, Cotter RJ (2012) Robust Two-Dimensional Separation of Intact Proteins for Bottom-Up Tandem Mass Spectrometry of the Human CSF Proteome. J Proteome Res.
7. Orchard PJ, Lund T, Miller W, Rothman SM, Raymond G, et al. (2011) Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy. J Neuroinflammation 8: 144.
8. Lund TC, Stadem PS, Panoskaltsis-Mortari A, Raymond G, Miller WP, et al. (2012) Elevated cerebral spinal fluid cytokine levels in boys with cerebral adrenoleukodystrophy correlates with MRI severity. PLoS One 7: e32218.
9. Loes DJ, Hite S, Moser H, Stillman AE, Shapiro E, et al. (1994) Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol 15: 1761-1766.
10. Miller WP, Rothman SM, Nascene D, Kivisto T, Defor TE, et al. (2011) Outcomes following allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood.
11. Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, et al. (1997) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. Journal of Neuroimmunology 84: 143-150.
12. Fuvesi J, Hanrieder J, Bencsik K, Rajda C, Kovacs SK, et al. (2012) Proteomic analysis of cerebrospinal fluid in a fulminant case of multiple sclerosis. Int J Mol Sci 13: 7676-7693.
13. Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, et al. (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. Brain 124: 493-498.
14. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC, (1996) Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46: 1626-1632.
15. Rosenberg GA, Yang Y, (2007) Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 22: E4.
16. Chang S, Young BD, Li S, Qi X, Richardson JA, et al. (2006) Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126: 321-334.
17. Mandal M, Mandal A, Das S, Chakraborti T, Sajal C, (2003) Clinical implications of matrix metalloproteinases. Mol Cell Biochem 252: 305-329.
18. Brew K, Dinakarpandian D, Nagase H, (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochem Biophys Acta 147: 267-283.
19. Rosenberg GA, (2002) Matrix metalloproteinases in neuroinflammation. Glia 39: 279-291.
20. Schluter A, Espinosa L, Fourcade s, Galino J, Lopez E, et al. (2011) Functional genomic analysis unravels a metabolic- inflammatory interplay in adrenoleukodystrophy. Human Molecular Genetics: 1-16.
21. Eichler FS, Ren JQ, Cossoy M, Rietsch AM, Nagpal S, et al. (2008) Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann Neurol 63: 729-742.
22. Maeda A, Sobel R, (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55: 300-309.
23. Stoll G, Jander S, Schroeter M, (2002) Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 513: 87-113.
24. Kessenbrock K, Plaks V, Werb Z, (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67.
25. Liu Y, Zhou Y, Zhang XS, Shen BZ, (2011) Expression of VEGF and MMP-9 and MRI imaging changes in cerebral glioma. Oncol Lett 2: 1171-1175.
26. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR, (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21: 75-80.
27. Rosenberg GA, (1995) Matrix metalloproteinases in brain injury. J Neurotrauma 12: 833-842.
28. Castro MM, Kandasamy AD, Youssef N, Schulz R, (2011) Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res 64: 551-560.
29. Kieseier BC, Seifert T, Giovannoni G, Hartung HP, (1999) Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 53: 20-25.
30. Phillips JP, Lockman LA, Shapiro EG, Blazar BR, Loes DJ, et al. (1994) CSF findings in adrenoleukodystrophy: correlation between measures of cytokines, IgG production, and disease severity. Pediatr Neurol 10: 289-294.